Metabolic effects of beta-blockers: importance of dissociating newer from conventional agents.
Sarafidis
Pantelis A
PA
Bakris
George L
GL
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001578:Benzopyrans / Q000494:pharmacology / Q000627:therapeutic use*; D050260:Carbohydrate Metabolism / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000503:physiopathology; D004983:Ethanolamines / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D007333:Insulin Resistance; D000068577:Nebivolol; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D012107:Research Design
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D001578:Benzopyrans; D004983:Ethanolamines; D000068577:Nebivolol